Advanced Search

Project: Phenotypes and body mass in women with PCOS identified in Referral vs. Unselected populations: systematic review and meta-analysis

Public Report Complete



Project Summary

Title and Description


Key Questions



Associated Studies (each link opens a new tab)

Title Author Year
Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. Dewailly D., Catteau-Jonard S., Reyss AC., Leroy M., Pigny P. 2006
Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Shroff R., Syrop CH., Davis W., Van Voorhis BJ., Dokras A. 2007
Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Guastella E., Longo RA., Carmina E. 2010
Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. Zhao Y., Fu L., Li R., Wang LN., Yang Y., Liu NN., Zhang CM., Wang Y., Liu P., Tu BB., Zhang X., Qiao J. 2012
A 20-year follow-up of young women with polycystic ovary syndrome. Carmina E., Campagna AM., Lobo RA. 2012
The frequency of metabolic syndrome is higher among PCOS Brazilian women with menstrual irregularity plus hyperandrogenism. Melo AS., Vieira CS., Romano LG., Ferriani RA., Navarro PA. 2011
Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Yilmaz M., Isaoglu U., Delibas IB., Kadanali S. 2011
Metabolic profile of the different phenotypes of polycystic ovary syndrome in two Latin American populations. Ladrón de Guevara A., Fux-Otta C., Crisosto N., Szafryk de Mereshian P., Echiburú B., Iraci G., Perez-Bravo F., Sir-Petermann T. 2014
Metabolic profile of the different phenotypes of polycystic ovary syndrome in two Latin American populations. Ladrón de Guevara A., Fux-Otta C., Crisosto N., Szafryk de Mereshian P., Echiburú B., Iraci G., Perez-Bravo F., Sir-Petermann T. 2014
Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Li R., Zhang Q., Yang D., Li S., Lu S., Wu X., Wei Z., Song X., Wang X., Fu S., Lin J., Zhu Y., Jiang Y., Feng HL., Qiao J. 2013
Cardiovascular and metabolic characteristics of infertile Chinese women with PCOS diagnosed according to the Rotterdam consensus criteria. Guo M., Chen ZJ., Macklon NS., Shi YH., Westerveld HE., Eijkemans MJ., Fauser BC., Goverde AJ. 2010
CD4(+)CD28(null) T lymphocyte frequency, a new marker of cardiovascular risk: relationship with polycystic ovary syndrome phenotypes. Moro F., Morciano A., Tropea A., Sagnella F., Palla C., Scarinci E., Cosentino N., Niccoli G., Liuzzo G., Crea F., Lanzone A., Apa R. 2012
Characteristics of abnormal menstrual cycle and polycystic ovary syndrome in community and hospital populations. Ma YM., Li R., Qiao J., Zhang XW., Wang SY., Zhang QF., Li L., Tu BB., Zhang X. 2010
Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. Zhang HY., Zhu FF., Xiong J., Shi XB., Fu SX. 2009
Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in the Croatian population. Baldani DP., Skrgatić L., Simunić V., Zlopasa G., Canić T., Trgovcić I. 2013
Diagnostic criteria for polycystic ovary syndrome in Taiwanese Chinese women: comparison between Rotterdam 2003 and NIH 1990. Hsu MI., Liou TH., Chou SY., Chang CY., Hsu CS. 2007
Different phenotypes of polycystic ovary syndrome in Turkish women: clinical and endocrine characteristics. Ates S., Sevket O., Sudolmus S., Dane B., Ozkal F., Uysal O., Dansuk R. 2013
Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). Georgopoulos NA., Papadakis E., Armeni AK., Katsikis I., Roupas ND., Panidis D. -- Not Found --
Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Panidis D., Tziomalos K., Misichronis G., Papadakis E., Betsas G., Katsikis I., Macut D. 2012
Is hyperandrogenemia protective for fibrocystic breast disease in PCOS? Ozkaya E., Cakir E., Cinar M., Kara F., Baser E., Cakir C., Kucukozkan T. 2012
Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Wijeyaratne CN., Seneviratne Rde A., Dahanayake S., Kumarapeli V., Palipane E., Kuruppu N., Yapa C., Seneviratne Rde A., Balen AH. 2011
Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare. Gabrielli L., Aquino EM. 2012
Prevalence of polycystic ovary syndrome and related disorders in mexican women. Moran C., Tena G., Moran S., Ruiz P., Reyna R., Duque X. 2010
Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Yildiz BO., Bozdag G., Yapici Z., Esinler I., Yarali H. 2012
Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. Sahmay S., Atakul N., Oncul M., Tuten A., Aydogan B., Seyisoglu H. 2013
The different phenotypes of polycystic ovary syndrome: no advantages for identifying women with aggravated insulin resistance or impaired lipids. Cupisti S., Haeberle L., Schell C., Richter H., Schulze C., Hildebrandt T., Oppelt PG., Beckmann MW., Dittrich R., Mueller A. 2011
The prevalence of phenotypic subgroups in Greek women with polycystic ovarian syndrome. Vaggopoulos V., Trakakis E., Panagopoulos P., Basios G., Salloum I., Christodoulaki C., Chrelias C. 2013
The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. March WA., Moore VM., Willson KJ., Phillips DI., Norman RJ., Davies MJ. 2010
The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Tehrani FR., Simbar M., Tohidi M., Hosseinpanah F., Azizi F. 2011
The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Lauritsen MP., Bentzen JG., Pinborg A., Loft A., Forman JL., Thuesen LL., Cohen A., Hougaard DM., Nyboe Andersen A. 2014
Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Diamanti-Kandarakis E., Panidis D. 2007
The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Tehrani FR., Rashidi H., Khomami MB., Tohidi M., Azizi F. 2014
Characteristics of abnormal menstrual cycle and polycystic ovary syndrome in community and hospital populations. Ma YM., Li R., Qiao J., Zhang XW., Wang SY., Zhang QF., Li L., Tu BB., Zhang X. 2010
The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. Mehrabian F., Khani B., Kelishadi R., Kermani N. 2011
Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma? Belosi C., Selvaggi L., Apa R., Guido M., Romualdi D., Fulghesu AM., Lanzone A. 2006
Adrenocortical steroid response to ACTH in different phenotypes of non-obese polycystic ovary syndrome. Cinar N., Harmanci A., Aksoy DY., Aydin K., Yildiz BO. 2012
Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes. Aziz M., Sidelmann JJ., Faber J., Wissing ML., Naver KV., Mikkelsen AL., Nilas L., Skouby SO. 2015
Characteristics and contributions of hyperandrogenism to insulin resistance and other metabolic profiles in polycystic ovary syndrome. Huang R., Zheng J., Li S., Tao T., Ma J., Liu W. 2015
Are Dieting and Dietary Inadequacy a Second Hit in the Association with Polycystic Ovary Syndrome Severity? Huijgen NA., Laven JS., Labee CT., Louwers YV., Willemsen SP., Steegers-Theunissen RP. 2015
Antioxidant properties of high-density lipoproteins are impaired in women with polycystic ovary syndrome. Zhang J., Zhang Y., Liu H., Bai H., Wang Y., Jiang C., Fan P. 2015
A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Jamil AS., Alalaf SK., Al-Tawil NG., Al-Shawaf T. 2015
The Role of Anti-Müllerian Hormone in the Characterization of the Different Polycystic Ovary Syndrome Phenotypes. Romualdi D., Di Florio C., Tagliaferri V., De Cicco S., Gagliano D., Immediata V., Lanzone A., Guido M. 2016
Hyperandrogenism and phenotypes of polycystic ovary syndrome are not associated with differences in obstetric outcomes. Mumm H., Jensen DM., Sørensen JA., Andersen LL., Ravn P., Andersen M., Glintborg D. 2015




Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/